I had the opportunity to write a comment about findings from a large vaccination cohort study in Scotland. I use the comment to discuss some of the challenges of observational vaccine studies and the potential for lingering bias. THREAD 1/11 https://t.co/XO39e7Vd3h
Regarding vaccine safety, regulators are in a tough position. Transparency is a good principle. But one thing to do better is to limit the dead time between an announcement and the details of its rationale (the media briefing). Here be dragons. 1/3
A few comments on the J&J news: – A pause is not permanent – The FDA is cautious because it’s important to be responsive to any safety concern; long-term trust is easily lost – We have additional insights from the AZ vaccine used in Europe, which is also adenovirus-based 1/2 https://t.co/ShdWrBo7rn
